Sign in

IVA on Nasdaq

Inventiva S.A.

Inventiva S.A. is a pharmaceutical preparations company, listed on Nasdaq (IVA).1

Price unavailable

Last updated Oct 21, 2026.

Overview

Compare with Nanobiotix S.A., Morphosys or Ascendis Pharma A/S, or pick any stock.

  • TickerIVA on Nasdaq1
  • IndustryPharmaceutical Preparations1
  • HeadquartersI01
  • Incorporated inFrance2
  • Business address50 Rue De Dijon, Daix, I0 211212
  • Filer categoryAccelerated filer2

See how the biggest companies compare on our leaderboards

We were founded in 2011 and incorporated in France in 2016 under the legal name Inventiva S.A. as a société anonyme, or S.A., for a period of 99 years. Our principal executive offices are located at 50 rue de Dijon, 21121 Daix, France and our telephone number is +33 3 80 44 75 00. We are registered at the Dijon Trade and Companies Register ( Registre du commerce et des sociétés ) under the number 537 530 255. Our agent for service of process in the United States is Cogency Global Inc., 122 East 42nd Street, 18th Floor, New York, New York 10168.3 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from. Figures are in EUR, the currency the company reports in.

Key numbers, fiscal 2024

-1060.6%Operating margin4
-47.4%Revenue growth, 20244

Where the money goes

Where each dollar of revenue went, fiscal 2024

  • Research and development88¢90.9M EUR
  • Interest12¢12.2M EUR
  • Income tax0¢313.0K EUR

Out of 9.2M EUR in revenue.4

Financial statements

Revenue567849.2M EUR in 2024+188% since 2018
05.0M EUR10.0M EUR15.0M EUR20.0M EUR2018: 3.2M EUR3.2M EUR20182019: 7.0M EUR7.0M EUR2019+119%2020: 372.0K EUR372.0K EUR2020−95%2021: 4.2M EUR4.2M EUR2021+1027%2022: 12.2M EUR12.2M EUR2022+190%2023: 17.5M EUR17.5M EUR2023+44%2024: 9.2M EUR9.2M EUR2024−47%
Operating income56784-97.6M EUR in 2024+197% since 2018
-150.0M EUR-100.0M EUR-50.0M EUR02018: -32.9M EUR-32.9M EUR20182019: -30.3M EUR-30.3M EUR2019−8%2020: -29.7M EUR-29.7M EUR2020−2%2021: -52.1M EUR-52.1M EUR2021+75%2022: -57.1M EUR-57.1M EUR2022+10%2023: -102.7M EUR-102.7M EUR2023+80%2024: -97.6M EUR-97.6M EUR2024−5%

Every line of the income statement as filed: the last 3 fiscal years, latest first.9

Period ending2025-12-312024-12-312023-12-31
Revenues4.5M EUR9.2M EUR17.5M EUR
Other income3.4M EUR5.5M EUR5.7M EUR
Total revenues and other income7.9M EUR14.7M EUR23.2M EUR
Research and development costs-87.0M EUR-90.9M EUR-110.0M EUR
Marketing - Business development expenses-5.0M EUR-2.0M EUR-2.0M EUR
General and administrative expenses-47.9M EUR-15.8M EUR-13.8M EUR
Other operating income (expenses)-9.0M EUR-3.6M EUR-44.0K EUR
Operating profit (loss)-141.0M EUR-97.6M EUR-102.7M EUR
Financial income4.2M EUR2.9M EUR1.8M EUR
Financial expenses-216.9M EUR-88.9M EUR-6.9M EUR
Financial income (loss)-212.8M EUR-86.0M EUR-5.1M EUR
Share of net profit (loss) - Equity method-350.0K EUR-313.0K EUR-2.0M EUR
Income tax-22.0K EUR-313.0K EUR-607.0K EUR
Net loss for the period-354.1M EUR-184.2M EUR-110.4M EUR
Basic loss per share-1.90 EUR-3.08 EUR-2.43 EUR
Diluted loss per share-1.90 EUR-3.08 EUR-2.43 EUR
Weighted average number of shares outstanding used to calculate basic loss per share186.8M shares59.8M shares45.4M shares
Weighted average number of shares outstanding used to calculate diluted loss per share186.8M shares59.8M shares45.4M shares

Compare Inventiva S.A. with another company

Corporate structure

Inventiva S.A. sits at the top of its group. 1 entity on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Inventiva S.A.

  • Deep Track Capital, LP Filed SCHEDULE 13G/A on Inventiva S.A., latest May 15, 2026 (2 filings since Jan 30, 2026)
  • New Enterprise Associates 17, L.P. Filed SCHEDULE 13D/A on Inventiva S.A., latest Apr 1, 2026 (4 filings since May 3, 2024)
  • Andera Partners Filed SCHEDULE 13G/A on Inventiva S.A., latest Feb 17, 2026 (3 filings since Apr 14, 2025)
  • Crossover I. Sofinnova Filed SCHEDULE 13G/A on Inventiva S.A., latest Feb 17, 2026 (5 filings since Feb 11, 2022)
  • GREAT POINT PARTNERS LLC Filed SCHEDULE 13G/A on Inventiva S.A., latest Feb 17, 2026 (3 filings since Jun 20, 2025)
  • EVENTIDE ASSET MANAGEMENT, LLC Filed SCHEDULE 13G/A on Inventiva S.A., latest Feb 13, 2026 (2 filings since May 15, 2025)
  • BIOTECHNOLOGY VALUE FUND L P Filed SCHEDULE 13D/A on Inventiva S.A., latest Nov 19, 2025 (6 filings since Sep 25, 2023)
  • Samsara BioCapital, L.P. Filed SCHEDULE 13D/A on Inventiva S.A., latest Nov 19, 2025 (2 filings since Oct 21, 2025)
  • PERCEPTIVE ADVISORS LLC Filed SCHEDULE 13G/A on Inventiva S.A., latest Nov 14, 2025 (2 filings since Mar 26, 2025)
  • Yiheng Capital Management, L.P. Filed SCHEDULE 13G/A on Inventiva S.A., latest Nov 13, 2025 (4 filings since Feb 14, 2023)
  • Invus Global Management, LLC Filed SCHEDULE 13G/A on Inventiva S.A., latest Jul 31, 2025 (2 filings since Mar 31, 2025)
  • Pierre Broqua Filed SCHEDULE 13G/A on Inventiva S.A., latest Feb 14, 2025
  • Inventiva S.A. I0

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Inventiva S.A. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, net5.0M EUR4 Dec 31, 20249.1M EUR4 Dec 31, 2023−45.2%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents96.6M EUR4 Dec 31, 202426.9M EUR4 Dec 31, 2023+258.7%

Intangibles and goodwill

ItemLatestA year beforeChange
Intangible assets, net (excluding goodwill)48.0K EUR4 Dec 31, 2024541.0K EUR4 Dec 31, 2023−91.1%

Inventory

ItemLatestA year beforeChange
Inventory, total0 EUR4 Dec 31, 2024417.0K EUR4 Dec 31, 2023−100.0%

Calendar

Drug trials and FDA: coming up

  1. Sep 30, 2027Phase 3 trial readout expected Phase 3 trial of IVA337 in NASH - Nonalcoholic Steatohepatitis: primary completion expected Sep 30, 2027 (ClinicalTrials.gov NCT04849728).10

Drug trials and FDA: recently

  1. May 8, 2024Phase 2 trial completed Phase 2 trial of Lanifibranor and Empagliflozin in NASH - Nonalcoholic Steatohepatitis: primary completion May 8, 2024, results posted Sep 9, 2026 (ClinicalTrials.gov NCT05232071).11

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). Trials from ClinicalTrials.gov, as the sponsor registered them (expected dates are the sponsor's own and often move); approvals and advisory committee meetings from the FDA. The FDA does not publish its decision (PDUFA) dates. The full markets calendar

Filings

176 filings to the SEC since October 2021: 5 annual reports, 37 large holders, 134 other. The latest 20:

  1. Oct 6, 20266-K EDGAR
  2. Sep 28, 20266-K EDGAR
  3. Sep 3, 20266-K EDGAR
  4. Sep 1, 20266-K EDGAR
  5. Jul 30, 20266-K/A EDGAR
  6. Jul 29, 20266-K EDGAR
  7. Jul 9, 20266-K EDGAR
  8. Jul 6, 20266-K EDGAR
  9. Jun 12, 20266-K EDGAR
  10. Jun 12, 20266-K EDGAR
  11. Jun 9, 20266-K EDGAR
  12. Jun 3, 20266-K EDGAR
  13. Jun 3, 20266-K EDGAR
  14. Jun 2, 2026424B5 EDGAR
  15. Jun 2, 2026FWP EDGAR
  16. Jun 2, 2026F-3ASR EDGAR
  17. May 26, 20266-K EDGAR
  18. May 22, 20266-K EDGAR
  19. May 15, 2026SCHEDULE 13G/A EDGAR
  20. Apr 22, 20266-K EDGAR

The 176 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 86. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Caligan Partners LP8,163,191$30.9M1.5%+3,188,285
Samsara Biocapital, LLC6,314,805$23.9M2.0%+1,120,000
Nantahala Capital Management, LLC5,372,786$20.3M0.6%New
Paradigm Biocapital Advisors LP4,000,000$15.1M0.3%No change
Andera Partners3,633,181$13.7M6.7%+1,815,000
ADAR1 Capital Management, LLC3,606,656$13.6M0.6%+1,432,258
Millennium Management LLC3,512,174$13.3M0.0%+524,561
Trails Edge Capital Partners, LP2,657,997$10.0M1.6%No change
Franklin Resources Inc2,642,611$10.0M0.0%+181,046
Squadron Capital Management LLC2,435,000$9.2M3.2%+1,900,000
Woodline Partners LP2,323,149$8.8M0.0%New
Aberdeen Group plc2,307,773$8.7M0.0%New
UBS Group AG2,305,192$8.7M0.0%−13,501
Boothbay Fund Management, LLC2,003,782$7.6M0.1%+533,375
Patient Square Capital LP1,967,171$7.4M1.2%New
NEXTBio Capital Management LP1,787,984$6.8M3.1%+454,500
Citadel Advisors LLC1,784,566$6.7M0.0%+1,719,616
Ameriprise Financial Inc1,697,148$6.4M0.0%+852,933
Point72 Asset Management, L.P.1,683,012$6.4M0.0%+726,791
Integral Health Asset Management, LLC1,520,000$5.7M0.2%+1,120,000
Yu Fan1,500,000$5.7M5.3%No change
NEA Management Company, LLC1,462,586$5.5M0.3%No change
Stempoint Capital LP1,426,320$5.4M0.9%New
Propel Bio Management, LLC1,281,212$4.8M2.5%+556,534
Kingdon Capital Management, L.l.c.1,270,000$4.8M0.6%New

13F reports cover disclosed long positions in U.S. stocks only.

SEC filer profile

How Inventiva S.A. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARInventiva S.A.1
  • CIK0001756594
  • Filer statusAccelerated filer not an emerging growth company; not a shell company3
  • Incorporated inI03
  • Fiscal year endsDecember 311
  • Industry code (SIC)2834 Pharmaceutical Preparations1
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
  • Business address50 Rue De Dijon, Daix, I0 211211
  • Phone333804475001
  • Shares outstanding193,236,978 shares as of Dec 31, 20253
  • AuditorKPMG SA, Paris La Defense, France PCAOB ID 1253; it also attests to the company’s internal control over financial reporting3
  • On EDGAR sinceApr 10, 20201
  • Filings227 in all: 6-K (145), SCHEDULE 13G/A (13), 20-F (6), SCHEDULE 13D/A (6), SCHEDULE 13G (6), SC 13D/A (5), SC 13G (5), 424B5 (4)1
    All 26 form types

    CORRESP (4), FWP (4), SC 13G/A (4), UPLOAD (4), 6-K/A (3), DRSLTR (2), EFFECT (2), F-1/A (2), F-3 (2), SC 13D (2), 20-F/A (1), 424B4 (1), 8-A12B (1), CERT (1), DRS (1), F-1 (1), F-3ASR (1), SCHEDULE 13D (1)

  • Latest filingsAnnual report (20-F) Apr 8, 2026

Securities registered for trading

ClassSymbolExchange
American Depositary Shares, each representing one ordinary share, nominal value €0.01 per shareIVANasdaq
Ordinary shares, nominal value €0.01 per shareNasdaq

From the cover page of the 20-F filed Apr 8, 2026 (Section 12(b) of the Exchange Act).3

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24